A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...